SG11201710164QA - Positive allosteric modulators of muscarinic m2 receptor - Google Patents

Positive allosteric modulators of muscarinic m2 receptor

Info

Publication number
SG11201710164QA
SG11201710164QA SG11201710164QA SG11201710164QA SG11201710164QA SG 11201710164Q A SG11201710164Q A SG 11201710164QA SG 11201710164Q A SG11201710164Q A SG 11201710164QA SG 11201710164Q A SG11201710164Q A SG 11201710164QA SG 11201710164Q A SG11201710164Q A SG 11201710164QA
Authority
SG
Singapore
Prior art keywords
muscarinic
receptor
positive allosteric
allosteric modulators
modulators
Prior art date
Application number
SG11201710164QA
Inventor
Henrik Teller
Alexander Straub
Markus Brechmann
Thomas Müller
Mark Meininghaus
Katrin Nowak-Reppel
Hanna Tinel
Klaus Münter
Daniela Fliegner
Thomas Mondritzki
Arapinis Melissa Boultadakis
Tobias Marquardt
Alexandros Vakalopoulos
Anne-Sophie Rebstock
Matthias Beat Wittwer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201710164QA publication Critical patent/SG11201710164QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201710164QA 2015-06-09 2016-06-06 Positive allosteric modulators of muscarinic m2 receptor SG11201710164QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15171127 2015-06-09
EP16156676 2016-02-22
PCT/EP2016/062737 WO2016198342A1 (en) 2015-06-09 2016-06-06 Positive allosteric modulators of muscarinic m2 receptor

Publications (1)

Publication Number Publication Date
SG11201710164QA true SG11201710164QA (en) 2018-01-30

Family

ID=56101466

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201710164QA SG11201710164QA (en) 2015-06-09 2016-06-06 Positive allosteric modulators of muscarinic m2 receptor

Country Status (27)

Country Link
US (2) US10435403B2 (en)
EP (2) EP3692991A1 (en)
JP (1) JP6908536B2 (en)
KR (1) KR20180016485A (en)
CN (1) CN107949562B (en)
AU (1) AU2016274433B2 (en)
BR (1) BR112017026561A2 (en)
CA (1) CA2988468A1 (en)
CL (1) CL2017003124A1 (en)
CO (1) CO2017012622A2 (en)
CR (1) CR20170566A (en)
CU (1) CU20170158A7 (en)
DO (1) DOP2017000288A (en)
EA (1) EA035465B1 (en)
EC (1) ECSP17081322A (en)
HK (1) HK1254348A1 (en)
IL (2) IL256119A (en)
MX (1) MX370113B (en)
NI (1) NI201700154A (en)
PE (1) PE20180252A1 (en)
PH (1) PH12017502224A1 (en)
SG (1) SG11201710164QA (en)
TN (1) TN2017000498A1 (en)
TW (1) TW201716405A (en)
UY (1) UY36714A (en)
WO (1) WO2016198342A1 (en)
ZA (1) ZA201800125B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246864B2 (en) 2016-06-02 2022-02-15 Ads Therapeutics Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
WO2018011017A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (en) * 2016-09-14 2019-03-14 Bayer Ag 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190086A1 (en) * 2016-10-21 2019-04-18 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
CN110215899B (en) * 2019-04-01 2022-03-25 重庆科技学院 Amino acid functionalized metal organic framework material and preparation method and application thereof
BR112021026662A2 (en) * 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Methods to alleviate pterygium-associated concern about the appearance of the eye
CN111057045A (en) * 2019-12-18 2020-04-24 安徽红杉生物医药科技有限公司 HCV NS3/4A protease inhibitor intermediate, and synthesis method and application thereof
CN114105881B (en) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 Platelet aggregation inhibitor, and preparation method and application thereof
CN113072480B (en) * 2021-04-13 2022-09-30 常州佳德医药科技有限公司 Chiral (-) -5-azaspiro [2.4] heptane-7-alcohol, preparation method and application

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906365A1 (en) 1988-07-15 1990-01-18 Bayer Ag 7- (1-PYRROLIDINYL) -3-CHINOLONE AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES, METHOD AND SUBSTITUTED (OXA) DIAZABICYCLOOCTANES AND NONANESE AS INTERMEDIATE PRODUCTS, AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THEM
IT1239283B (en) * 1989-11-08 1993-10-19 Erba Carlo Spa USE OF A MUSCARINIC AGENT ALONE OR TOGETHER WITH A KNOWN ANTIARRHYTHMIC DRUG FOR THE PREVENTION AND / OR TREATMENT OF VENTRICULAR ARRHYTHMIA.
CA2168764C (en) 1993-08-13 2000-01-18 Sung June Yoon Novel quinolone carboxylic acid derivatives
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
JP2005511743A (en) 2001-12-13 2005-04-28 ウォックハート・リミテッド A new generation of triple-targeted chiral broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, methods for their preparation, compositions, and pharmaceutical use
CN1168446C (en) * 2002-08-26 2004-09-29 夏国瑾 Application of arecaline hydrobromide as medicine for arrhythmia
MXPA05012619A (en) * 2003-05-21 2006-02-08 Univ Texas Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure.
JP2005012561A (en) 2003-06-19 2005-01-13 Sony Corp Image processing apparatus, image processing method, and image projector
MXPA06000675A (en) * 2003-07-24 2006-04-19 Astellas Pharma Inc Quinolone derivative or salt thereof.
WO2005026145A2 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
WO2005026165A1 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
DE10343098A1 (en) * 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydroquinoxalines and their use
WO2005049602A1 (en) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Quinolone antibacterial agents
MXPA06006532A (en) 2003-12-09 2006-08-23 Vertex Pharma Naphthyridine derivatives and their use as modulators of muscarinic receptors.
WO2005112949A1 (en) * 2004-05-20 2005-12-01 Diamedica Inc. Use of drug combinations for treating insulin resistance
AR057555A1 (en) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd A PHOSPHODIESTERASE A-4 4-OXO-1- (3-REPLACED PHENYL-1,4-DIHIDRO-1,8-NAFTIRIDIN-3-CARBOXAMIDE AND A PREPARATION PROCEDURE OF THE SAME
CN101411705B (en) * 2007-10-17 2011-06-01 北京赛德维康医药研究院 Pharmaceutical composition for preventing and treating atherosclerosis
WO2010093341A1 (en) 2009-02-10 2010-08-19 Janssen Pharmaceutica N.V. C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents
PL2512243T3 (en) 2009-12-17 2016-09-30 Quinoline amide m1 receptor positive allosteric modulators
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
CN103183676B (en) * 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 A group of 1-substituted-1, 8-naphthyridine formamide derivatives and preparation and application thereof
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
AR102487A1 (en) 2014-11-03 2017-03-01 Bayer Pharma AG DERIVATIVES OF PHENILTRIAZOL REPLACED WITH HYDROXIALQUIL AND ITS USES
CA2990277C (en) 2015-06-09 2021-10-26 Je Il Pharmaceutical Co., Ltd. Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
SG10201911849SA (en) 2015-06-09 2020-01-30 Abbvie Inc Nuclear receptor modulators
WO2018011017A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (en) 2016-09-14 2019-03-14 Bayer Ag 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof

Also Published As

Publication number Publication date
EP3307741B1 (en) 2020-10-28
CO2017012622A2 (en) 2018-03-28
DOP2017000288A (en) 2018-01-31
CL2017003124A1 (en) 2018-06-01
AU2016274433B2 (en) 2020-07-16
JP2018516970A (en) 2018-06-28
PE20180252A1 (en) 2018-02-02
EP3692991A1 (en) 2020-08-12
US20190367516A1 (en) 2019-12-05
AU2016274433A1 (en) 2018-01-04
PH12017502224A1 (en) 2018-06-04
ZA201800125B (en) 2019-07-31
US20180297994A1 (en) 2018-10-18
EA201890002A1 (en) 2018-04-30
ECSP17081322A (en) 2018-01-31
IL256119A (en) 2018-02-28
CA2988468A1 (en) 2016-12-15
HK1254348A1 (en) 2019-07-19
EA035465B1 (en) 2020-06-22
UY36714A (en) 2016-12-30
CR20170566A (en) 2018-03-20
US10435403B2 (en) 2019-10-08
TW201716405A (en) 2017-05-16
IL272017A (en) 2020-02-27
CU20170158A7 (en) 2018-06-05
WO2016198342A1 (en) 2016-12-15
JP6908536B2 (en) 2021-07-28
MX370113B (en) 2019-12-02
CN107949562B (en) 2021-07-23
TN2017000498A1 (en) 2019-04-12
MX2017016055A (en) 2018-02-21
KR20180016485A (en) 2018-02-14
BR112017026561A2 (en) 2018-08-14
CN107949562A (en) 2018-04-20
EP3307741A1 (en) 2018-04-18
NI201700154A (en) 2018-10-19

Similar Documents

Publication Publication Date Title
IL283582A (en) Modulators of ror-gamma
HK1256599A1 (en) Modulators of ror-gamma
IL272017A (en) Positive allosteric modulators of muscarinic m2 receptor
HK1253558A1 (en) Farnesoid x receptor modulators
IL261807A (en) Allosteric modulators of nicotinic acetylcholine receptors
IL263500A (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
IL264951B (en) Muscarinic m1 receptor positive allosteric modulators
HK1247919A1 (en) Muscarinic m1 receptor positive allosteric modulators
HK1247914A1 (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
HK1254769A1 (en) Compositions comprising s1p receptor modulators